Advancements in the use of blood tests for cancer screening in women at high risk for endometrial and breast cancer

Future Oncology

Volumn 7, Issue 12, 2011, Pages 1399-1414

  Ambeba, Erica ^a   Linkov, Faina ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

barriers to screening; cancer screening; endometrial cancer; obesity; postmenopausal breast cancer; serum biomarkers

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CA 125 ANTIGEN; CD151 ANTIGEN; CYTOKERATIN 18; FETUIN A; HE4 PROTEIN; IMP3 PROTEIN; KALLIKREIN 6; MIDKINE; SERUM AMYLOID P; SEX HORMONE BINDING GLOBULIN; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN;

BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; ENDOMETRIUM CANCER; ENDOMETRIUM CYTOLOGY; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OBESITY; TUMOR MARKERS, BIOLOGICAL;

EID: 82455208819     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.127     Document Type: Review

References (114)

1. CDC. Vital signs: state-specific obesity prevalence among adults - United States, 2009. Morb. Mortal. Wkly Rep. 59(30), 951-955 (2010).
2. Singh GK, Siahpush M, Hiatt RA, Timsina LR. Dramatic increases in obesity and overweight prevalence and body mass index among ethnic-immigrant and social class groups in the United States, 1976-2008. J. Community Health 36(1), 94-110 (2011).
3. Winfree LE, Henretta MS, Hallowell PT, Modesitt SC. Pre-operative gynecologic evaluation of bariatric surgery patients: improving cancer detection in a high-risk population. J. Am. Coll. Surg. 211(2), 256-262 (2010).
4. Vasudevan AR, Wu H, Xydakis AM et al. Eotaxin and obesity. J. Clin. Endocrinol. Metab. 91(1), 256-261 (2006).
5. Cust AE, Armstrong BK, Friedenreich CM, Slimani M, Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control 18(3), 243-258 (2007).
6. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children (Volume 5). Elsevier Mosby, Inc., St Louis, MO, USA (2006).
7. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 18(10), 2569-2578 (2009).
8. Huber J, Kiefer FW, Zeyda M et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J. Clin. Endocrinol. Metab. 93(8), 3215-3221 (2008).
9. Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes. Res. 13(4), 710-716 (2005).
10. Rondini EA, Harvey AE, Steibel JP, Hursting SD, Fenton JI. Energy balance modulates colon tumor growth: interactive roles of insulin and estrogen. Mol. Carcinog. 50(5), 370-382 (2011).
11. Linkov F, Yurkovetsky Z, Lokshin A. Biomarker approaches to the development of cancer screening tests: can cancer blood tests become a routine health check-up? Future Oncol. 3(3), 295-298 (2007).
12. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2011).
13. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 366(9484), 491-505 (2005).
14. Yurkovetsky Z, Ta'asan S, Skates S et al. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol. Oncol. 107(1), 58-65 (2007).
15. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol. Oncol. 114(1), 121-127 (2009).
16. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am. J. Epidemiol. 165(3), 262-270 (2007).
17. Doll A, Abal M, Rigau M et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol. 108(3-5), 221-229 (2008).
18. Sherman ME, Sturgeon S, Brinton LA et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 10(10), 963-968 (1997).
19. Cocco E, Bellone S, El-Sahwi K et al. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Cancer 101(2), 335-341 (2009).
20. Felix AS, Weissfeld JL, Stone RA et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 21(11), 1851-1856 (2010).
21. Cocco E, Bellone S, El-Sahwi K et al. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 116(4), 843-851 (2010).
22. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J. Br. Menopause Soc. 9(1), 27-31 (2003).
23. Cust AE, Allen NE, Rinaldi S et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int. J. Cancer 120(12), 2656-2664 (2007).
24. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am. J. Obstet. Gynecol. doi:10.1016/j.ajog.2011.05.042 (2011) (Epub ahead of print).
25. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr. Soc. 60(1), 91-106 (2001).
26. Lu L,Risch H, Irwin ML et al. Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int. J. Cancer 129(5), 1237-1243 (2011).
27. Reeves KW, Carter GC, Rodabough RJ et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol. Oncol. 121(2), 376-382 (2011).
28. Park SL, Goodman MT, Zhang ZF, Kolonel LN, Henderson BE, Setiawan VW. Body size, adult BMI gain and endometrial cancer risk: the multiethnic cohort. Int. J. Cancer 126(2), 490-499 (2010).
29. McCullough ML, Patel AV, Patel R et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol. Biomarkers Prev. 17(1), 73-79 (2008).
30. Clark TJ, Barton PM, Coomarasamy A, Gupta JK, Khan KS. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG 113(5), 502-510 (2006).
31. Jacobs I, Gentry-Maharaj A, Burnell M et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 12(1), 38-48 (2011).
32. Sit AS, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol. Biomarkers Prev. 13(9), 1459-1465 (2004).
33. Fan B, Zhao Q, Zhang S, Wang T, Deng X. Assessment of transvaginal sonography combined with endometrial cytology as a mass screening method for endometrial cancer in Beijing. J. Int. Med. Res. 38(3), 803-809 (2010).
34. Savelli L, Ceccarini M, Ludovisi M et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet. Gynecol. 31(5), 560-566 (2008).
35. Nishimura Y, Watanabe J, Jobo T, Hattori M, Arai T, Kuramoto H. Cytologic scoring of endometrioid adenocarcinoma of the endometrium. Cancer 105(1), 8-12 (2005).
36. Ribeiro CT, Rosa-E-Silva JC, Silva-de-Sa MF et al. Hysteroscopy as a standard procedure for assessing endometrial lesions among postmenopausal women. Sao Paulo Med. J. 125(6), 338-342 (2007).
37. Tinelli R, Tinelli FG, Cicinelli E, Malvasi A, Tinelli A. The role of hysteroscopy with eye-directed biopsy in postmenopausal women with uterine bleeding and endometrial atrophy. Menopause 15(4 Pt 1), 737-742 (2008).
38. Kitajima K, Murakami K, Yamasaki E et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann. Nucl. Med. 22(2), 103-109 (2008).
39. Ramirez PT, Frumovitz M, Milam MR et al. Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy. Int. J. Gynecol. Cancer 20(8), 1344-1349 (2010).
40. Kitajima K, Murakami K, Yamasaki E et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur. J. Nucl. Med. Mol. Imaging 36(3), 362-372 (2009).
41. Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am. J. Obstet. Gynecol. 200(6), 640 E1-E8 (2009).
42. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J. Natl Cancer Inst. 103(3), 250-263 (2011).
43. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 9(1), R6 (2007).
44. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res. Treat. 129(2), 565-574 (2011).
45. Gerend MA, Pai M. Social determinants of black-white disparities in breast cancer mortality: a review. Cancer Epidemiol. Biomarkers Prev. 17(11), 2913-2923 (2008).
46. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66(17), 8327-8330 (2006).
47. Stead LA, Lash TL, Sobieraj JE et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 11(2), R18 (2009).
48. Hahn KM, Bondy ML, Selvan M et al. Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am. J. Epidemiol. 166(9), 1035-1044 (2007).
49. Ferrante JM, Chen PH, Jacobs A. Breast and cervical cancer screening in obese minority women. J. Womens Health (Larchmt) 15(5), 531-41 (2006).
50. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 13(4), 325-332 (2002).
51. Sauter ER, Scott S, Hewett J et al. Biomarkers associated with breast cancer are associated with obesity. Cancer Detect Prev. 32(2), 149-155 (2008).
52. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res. Treat. 123(3), 641-649 (2010).
53. Hursting SD. Inflammatory talk: linking obesity, NF-kappaB, and aromatase. Cancer Prev. Res. (Phila.) 4(3), 285-287 (2011).
54. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J. Clin. Oncol. 29(1), 4-7 (2011).
55. Subbaramaiah K, Howe LR, Bhardwaj P et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. (Phila.) 4(3), 329-46 (2011).
56. Singh AK, Pandey A, Tewary M et al. Obesity augmented breast cancer risk: a potential risk factor for Indian women. J. Surg. Oncol. 103(3), 217-222 (2011).
57. Stark A, Schultz D, Kapke A et al. Obesity and risk of the less commonly diagnosed subtypes of breast cancer. Eur. J. Surg. Oncol. 35(9), 928-935 (2009).
58. Saslow D, Boetes C, Burke W et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57(2), 5-89 (2007).
59. Fenton JJ, Barton MB, Geiger AM et al. Screening clinical breast examination: how often does it miss lethal breast cancer? J. Natl Cancer Inst. Monogr. 5(35), 67-71 (2005).
60. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225(1), 165-175 (2002).
61. Goldman LE, Walker R, Miglioretti DL et al. Accuracy of diagnostic mammography at facilities serving vulnerable women. Med. Care 49(1), 67-75 (2011).
62. Hooley RJ, Andrejeva L, Scoutt LM. Breast cancer screening and problem solving using mammography, ultrasound, and magnetic resonance imaging. Ultrasound Q 27(1), 23-47 (2011).
63. Mandelson MT, Oestreicher N, Porter PL et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J. Natl Cancer Inst. 92(13), 1081-1087 (2000).
64. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 351(5), 427-437 (2004).
65. Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol. 23(33), 8469-8476 (2005).
66. Moadel RM. Breast cancer imaging devices. Semin. Nucl. Med. 41(3), 229-241 (2011).
67. Schilling K, Narayanan D, Kalinyak JE et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur. J. Nucl. Med. Mol. Imaging 38(1), 23-36 (2011).
68. Ferrante JM, Fyffe DC, Vega ML et al. Family physicians' barriers to cancer screening in extremely obese patients. Obesity (Silver Spring) 18(6), 1153-1159 (2010).
69. Feldstein AC, Perrin N, Rosales AG, Schneider J, Rix MM, Glasgow RE. Patient barriers to mammography identified during a reminder program. J. Womens Health (Larchmt) 20(3), 421-428 (2011).
70. Mitchell RS, Padwal RS, Chuck AW, Klarenback SW. Cancer screening among the overweight and obese in Canada. Am. J. Prev. Med. 35(2), 127-132 (2008).
71. Amy NK, Aalborg A, Lyons P, Karanen L. Barriers to routine gynecological cancer screening for white and African-American obese women. Int. J. Obes. (Lond.) 30(1), 147-155 (2006).
72. Puhl R, Brownell KD. Bias, discrimination, and obesity. Obes. Res. 9(12), 788-805 (2001).
73. Destounis S, Newell M, Pinsky R. Breast imaging and intervention in the overweight and obese patient. AJR Am. J. Roentgenol. 196(2), 296-302 (2011).
74. Daley E, Alio A, Anstey EH, Chandler R, Dyer K, Helmy H. Examining barriers to cervical cancer screening and treatment in Florida through a socio-ecological lens. J. Community Health 36(1), 121-131 (2011).
75. Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr. Probl. Cancer 31(3), 157-181 (2007).
76. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol. Biomarkers Prev. 15(6), 1078-1082 (2006).
77. Linkov F, Gu Y, Arslan AA et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur. Cytokine Netw. 20(1), 21-26 (2009).
78. Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am. J. Obstet. Gynecol. 202(1), 73 E1-E5 (2010).
79. Bignotti E, Ragnoli M, Zanotti L et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br. J. Cancer 104(9), 1418-1425 (2011).
80. Kanat-Pektas M, Yenicesu O, Gungor T, Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch. Gynecol. Obstet. 281(4), 709-715 (2010).
81. Badolato R, Wang JM, Murphy WJ et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 180(1), 203-209 (1994).
82. Sung HJ, Ahn JM, Yoon YH et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J. Proteome Res. 10(3), 1383-1395 (2011).
83. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S et al. Expression of serum amyloid A in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J. Histochem. Cytochem. 58(11), 1015-1023 (2010).
84. Ramankulov A, Lein M, Johannsen M et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett. 269(1), 85-92 (2008).
85. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48(8), 1198-1205 (2002).
86. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab. 11(2), 54-60 (2000).
87. Diamandis EP, Scorilas A, Fracchioli S et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21(6), 1035-1043 (2003).
88. Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267-277 (2005).
89. Ni X, Zhang W, Huang KC et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br. J. Cancer 91(4), 725-731 (2004).
90. Hoffman BR, Katsaros D, Scorilas A et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 87(7), 763-771 (2002).
91. Santin AD, Diamandis EP, Bellone S et al. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin. Cancer Res. 11(9), 3320-3325 (2005).
92. Tanabe K, Matsumoto M, Ikematsu S et al. Midkine and its clinical significance in endometrial carcinoma. Cancer Sci. 99(6), 1125-1130 (2008).
93. Moore RG, Brown AK, Miller MC et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 110(2), 196-201 (2008).
94. Mueller-Pillasch F, Pohl B, Wilda M et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 88(1), 95-99 (1999).
95. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 32(2), 304-315 (2008).
96. Mhawech-Fauceglia P, Herrmann FR, Rai H et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 133(6), 899-908 (2010).
97. Voss MA, Gordon N, Maloney S et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br. J. Cancer 104(10), 1611-1618 (2011).
98. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 24(5B), 3221-3224 (2004).
99. Lumachi F, Basso SM, Bonamini M et al. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Anticancer Res. 30(6), 2331-2334 (2010).
100. Atahan K, Kupeli H, Gur S et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int. J. Med. Sci. 8(2), 148-155 (2011).
101. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8), 1296-1304 (2002).
102. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res. Treat. 96(1), 83-90 (2006).
103. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 376(Pt 1), 135-145 (2003).
104. Yi JK, Chang JW, Han W et al. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol. Biomarkers Prev. 18(5), 1357-1364 (2009).
105. Schaub NP, Jones KJ, Nyalwidhe JO et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J. Am. Coll. Surg. 208(5), 970-978 (2009).
106. Olofsson MH, Ueno T, Pan Y et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 13(11), 3198-3206 (2007).
107. Kadowaki M, Sangai T, Nagashima T et al. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J. Cancer Res. Clin. Oncol. 137(7), 1105-1115 (2011).
108. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int. J. Cancer 125(1), 9-14 (2009).
109. Ferrante JM, Chen PH, Crabtree BF, Wartenberg D. Cancer screening in women: body mass index and adherence to physician recommendations. Am. J. Prev. Med. 32(6), 525-531 (2007).
110. American Cancer Society: endometrial (uterine) cancer. www.cancer.org/acs/groups/cid/documents/webcontent/003097-pdf.pdf (Accessed 21 October 2011)
111. American Cancer Society: breast cancer: early detection. www.cancer.org/acs/groups/cid/documents/webcontent/003165-pdf.pdf (Accessed 21 October 2011)
112. National Cancer Institute: endometrial cancer. www.cancer.gov/ cancertopics/types/endometrial (Accessed 21 October 2011)
113. Medscape: uterine cancer. http://emedicine.medscape.com/article/258148- overview (Accessed 21 October 2011)
114. FIGO committee on gynecologic oncology: staging classifications and clinical practice guidelines for gynecologic cancers handbook. www.figo.org/files/figo-corp/docs/staging-booklet.pdf (Accessed 21 October 2011)